Alkermes (NASDAQ:ALKS) Downgraded by StockNews.com to “Buy”

Alkermes NASDAQALKS is a biopharmaceutical company that focuses on developing and commercializing innovative treatments for central nervous system disorders. The company's flagship product is Rytelig, an opioid antagonist used to treat opioid dependence in adults.

On Friday, StockNews.com downgraded shares of Alkermes NASDAQALKS from a strong-buy rating to a buy rating in a research note. This change reflects the company's recent performance and future prospects.

In addition to this downgrade, other equities research analysts have also recently issued research reports about the stock. For example, Piper Sandler increased their price target on shares of Alkermes from $35.00 to $39.00 and gave the company a "neutral" rating.

It's worth noting that the downgrade by StockNews.com is not necessarily indicative of the overall sentiment among analysts or investors. Other factors, such as the company's financial performance, regulatory environment, and competitive landscape, may also impact its stock price and outlook.